DRUG · Mapped RxNorm record
Toripalimab
Normalized identity: toripalimabView linked drug · Find medicine records ·
Find other trials using this name
Clinical trial
Neoadjuvant Toripalimab for Clinically Stage II-IIIB Resectable Non-small Cell Lung Cancer with EGFR Mutation and PD-L1 Positive Expression
NCT06269211
Drugs and interventions used in this trial
1 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
No matching interventions in this trial.
Study at a glance
Registry-backedNeoadjuvant Toripalimab for Clinically Stage II-IIIB Resectable Non-small Cell Lung Cancer with EGFR Mutation and PD-L1 Positive Expression
Design: INTERVENTIONAL · Status: RECRUITING · Phase: PHASE2
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Carcinoma, Non-Small-Cell Lungunresolved
Interventions
ToripalimabDRUG · verified · RxNorm: toripalimab
Sponsors & collaborators
Ruijin Hospitallead sponsor
Guangdong Provincial People's Hospitalcollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT06269211 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.